FT-4101 / BMS, Novo Nordisk - LARVOL DELTA

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials. (PubMed, Diabetes Obes Metab) - "FASN inhibition with 3 mg FT-4101 safely reduces hepatic DNL and steatosis in NAFLD patients."

Clinical • Journal • Addiction (Opioid and Alcohol) • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity • FASN • MRI

A Study of FT 4101 in Overweight/Obese Participants With NASH (clinicaltrials.gov) - P1/2; N=14; Terminated; Sponsor: Forma Therapeutics, Inc.; N=30 ➔ 14; Recruiting ➔ Terminated; sponsor decision

Clinical • Enrollment change • Trial termination • Genetic Disorders • Hepatology • Non-alcoholic Steatohepatitis • Obesity

INHIBITION OF FATTY ACID SYNTHASE (FASN) WITH FT-4101 REDUCES HEPATIC DE NOVO LIPOGENESIS (DNL) IN HEALTHY ADULT SUBJECTS. (AASLD 2019) - "Fatty acid synthase inhibition with single doses of FT-4101 is safe and well tolerated and significantly reduces hepatic DNL."

Clinical • FASN

"FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects https://t.co/oHLI8EjPfz" (@NewsFromBW)

Clinical

A Study of FT 4101 in Overweight/Obese Participants With NASH (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: Forma Therapeutics, Inc.

Clinical • New P1/2 trial